No abstract

No abstract

No abstract

The course of the epidermal regeneration after stripping of the corneal layer was comparatively investigated by means of the distribution and activity of various enzymes in clinically normal psoriatic skin and normal skin. The following results were obtained: (1) At first clinically healthy psoriatic skin and normal skin behave principally uniform. (2)The observed augmentation of the activity of various enzymes in psoriatic skin free from specific lesions is so much increased that it essentially corresponds to the condition of the psoriatic lesion although to a different intensity. (3) Differences in the reproduction of the corneal layer were observed. (4) The possible consequences of these findings for the course of the psoriatic reaction are discussed.

Most of the patients (86.6 %) suffered from chronic plaque pso− riasis with a mean age of 48.5 years. Psorcutan Beta ointment showed a very fast onset of action and a convincing global effica− cy on every parameter observed in this study. As soon as one week after the initiation of the study 44.1 % of the patients al− ready observed improvement of skin lesions, another 35 % at the time point of 14 days. Complete remission or at least advance im− provements were observed in 95 % after the 4 weeks of the initia− tion period. Tolerability was excellent for all formulations of Psorcutan and Psorcutan Beta. Only one single patient suffered from an adverse event (transient exacerbation of exanthematic psoriasis). The rapid onset of action of Psorcutan Beta, the short treatment duration, the excellent therapeutic effects and the tolerability of both Psorcutan and Psorcutan Beta in the long observation pe− riod, confirmed the best suitibility of these medications in the treatment of psoriasis vulgaris. In this post marketing surveillance study it was proven that the maximum efficacy was gained by Psorcutan Beta with a marked improvement of skin lesions. Stabilization of the skin state or further amelioration was obtained by a consequent daily appli− cation of Psorcutan. Vitamin D−3−analogues and corticosteroids have different modes of action in the treatment of psoriasis. Psorcutan Beta is the first Therapiestudie 448